Impact ledger
Johnson & Johnson (JNJ)
31 events mapped to this ticker since 2026-06-12.
Assumption changes
| Date | Assumption | Direction | Magnitude | Conf. |
|---|---|---|---|---|
| 2026-07-15 | revenue | Bullish | 101100000000.00 | 1.00 |
| 2026-07-15 | revenue | Bullish | 101100000000.00 | 1.00 |
| 2026-07-15 | revenue | Bullish | 101100000000.00 | 1.00 |
| 2026-07-15 | share_count | Bullish | — | 0.70 |
| 2026-07-15 | net_debt | Bullish | — | 0.70 |
| 2026-07-15 | revenue | Bullish | — | 0.70 |
| 2026-07-15 | margin | Bullish | 11.68 | 0.95 |
| 2026-07-15 | revenue | Bullish | 101100000000.00 | 1.00 |
Event impact log
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-07-17 | Event | Indirect competitive pressure in the broader pharmaceutical market, potentially influencing investor sentiment towards companies with less robust near-term pipeline catalysts. | watch | 1-3m | 0.20 |
| 2026-07-16 | Event | Market reaction to strong earnings and guidance, potentially influenced by profit-taking or broader market sentiment, creating a short-term dip. | watch | 1-5d | 0.60 |
| 2026-07-16 | Event | Investor sentiment shift due to perceived weakness in a key growth segment (MedTech) despite overall strong financial performance and raised guidance. This could lead to short-term re-evaluation of growth prospects. | watch | 1-3m | 0.60 |
| 2026-07-15 | Event | Strategic acquisition to enhance oncology pipeline and future revenue growth, balanced by acquisition costs and integration risks. | mixed | 1-5y | 0.60 |
| 2026-07-15 | Event | Direct financial performance and forward guidance disclosure. | watch | intraday | 0.90 |
| 2026-07-07 | Event | Increased institutional demand for high-dividend healthcare stocks, providing stability and income in a volatile market, potentially leading to capital appreciation. | Bullish | 1-3m | 0.65 |
| 2026-07-05 | Event | Increased competitive landscape in immunology, potential for further M&A activity in the sector. | watch | 1-3m | 0.20 |
| 2026-07-05 | Event | Increased competitive landscape in immunology, potentially affecting future growth prospects or R&D investment decisions. | watch | 1-3m | 0.20 |
| 2026-07-02 | Event | Minor competitive landscape shift in medical devices; potential for future M&A activity in the sector. | watch | 3-12m | 0.15 |
| 2026-06-30 | Event | Potential for increased competition in the surgical technology and medical device segments where Johnson & Johnson operates, particularly with its Ottava surgical robotics platform. | Bearish | 3-12m | 0.10 |
| 2026-06-30 | Event | As a large diversified healthcare company with pharmaceutical and medical device segments, J&J monitors advancements in oncology. This approval could signal emerging therapeutic areas or potential acquisition targets in the long term. | watch | 1-5y | 0.15 |
| 2026-06-30 | Event | Indirect competitive pressure in the broader dermatology/psoriasis market, particularly for biologics. | watch | 3-12m | 0.20 |
| 2026-06-30 | Event | Strategic M&A to offset patent cliff and acquire late-stage assets, potentially leading to increased R&D efficiency but also integration risks and acquisition costs. | mixed | 1-5y | 0.70 |
| 2026-06-26 | Event | Strategic pivot towards high-growth biologics and medical platforms, coupled with significant domestic investment, is expected to drive future revenue and profitability. | Bullish | 1-5y | 0.80 |
| 2026-06-26 | Event | Strategic shift towards high-growth segments (biologics, med-tech) and significant domestic investment to drive future revenue and profitability. | Bullish | 1-5y | 0.80 |
| 2026-06-26 | Event | As a diversified healthcare company with a presence in China, J&J could face increased compliance costs or potential tax adjustments if the trend of stricter tax enforcement continues. | watch | 3-12m | 0.20 |
| 2026-06-25 | Event | Similar to Pfizer, J&J's broad pharmaceutical and medical device presence could lead to strategic interest in the expanding vaccine market, or indirect benefits from overall healthcare spending increases. | watch | 3-12m | 0.30 |
| 2026-06-23 | Event | Potential for increased competition in the medical device and robotic surgery segments, where JNJ has investments and products. | watch | 3-12m | 0.10 |
| 2026-06-23 | Event | Increased competitive pressure in immunology market, potential for other M&A activity in the sector. | watch | 3-12m | 0.20 |
| 2026-06-23 | Event | Increased competitive landscape in immunology, specifically in atopic dermatitis and asthma, where J&J has products like Tremfya and Stelara (though Stelara is broader). May prompt strategic review of pipeline or M&A. | watch | 3-12m | 0.30 |
| 2026-06-22 | Event | Potential competitive pressure in the antidepressant market. J&J has a neuroscience pipeline and marketed products for depression (e.g., Spravato). | watch | 3-12m | 0.20 |
| 2026-06-22 | Event | Intensified competition in the immunology therapeutic area, potentially influencing market dynamics for J&J's immunology franchise. | watch | 1-3m | 0.20 |
| 2026-06-22 | Event | Potential competitive pressure in the immunology and inflammatory disease market. J&J has a significant immunology portfolio that could face new competition. | watch | 3-12m | 0.30 |
| 2026-06-22 | Event | Increased competitive pressure in the immunology market, potential for other large pharma companies to seek similar acquisitions. | watch | 1-3m | 0.30 |
| 2026-06-18 | Event | As a partner in Carvykti, LEGN's strengthened financial position could indirectly support the commercial success of the drug, but JNJ's exposure is diversified. | watch | 3-12m | 0.20 |
| 2026-06-17 | Event | Broader positive sentiment for oncology combination therapies, potentially benefiting J&J's oncology pipeline or existing treatments. | watch | 3-12m | 0.05 |
| 2026-06-15 | Event | Indirect competitive pressure in the inflammatory bowel disease (IBD) market, as SPY002 could become a significant competitor to existing or pipeline IBD treatments, potentially impacting sales of established drugs. | watch | 1-3m | 0.25 |
| 2026-06-15 | Event | Indirect competitive pressure. Johnson & Johnson has significant market share in immunology, including IBD. A successful new drug like SPY002 could introduce new competition and potentially impact J&J's long-term market position in this therapeutic area. | watch | 1-3m | 0.20 |
| 2026-06-12 | Event | While J&J has a diversified portfolio, increased M&A in the pharmaceutical segment could influence their strategic decisions regarding pipeline development and external growth opportunities. | watch | 1-3m | 0.20 |
| 2026-06-12 | Event | While diversified, J&J has a significant oncology segment. Strong performance from a competitor like AbbVie could intensify competition for pipeline assets, talent, or market share in specific oncology indications. | watch | 1-3m | 0.20 |
| 2026-06-12 | Event | Broader industry sentiment and investor expectations. While JNJ has a more diversified business, its pharmaceutical segment faces similar pressures. BMY's proactive cost management could raise investor expectations for efficiency across the sector. | watch | 3-12m | 0.20 |
This ledger is regenerated from Market Ontology's public event pipeline. For live alerts on new assumption changes for JNJ, start a trial or view the JNJ entity page.